New sedative could be safer for frail patients during medical procedures
NCT ID NCT07362173
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares remimazolam, a new ultra-short-acting sedative, to propofol in 200 patients aged 65 or older with serious health conditions. The goal is to see if remimazolam provides better heart and breathing stability during endoscopic procedures. Researchers will also measure patient and doctor satisfaction and recovery quality.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remimazolam
What this could lead to
If successful, remimazolam could become a safer sedation option for elderly or frail patients, reducing complications like low blood pressure or breathing problems.
What could go wrong
This is a phase 4 study with 200 participants, so results may not apply to all patients. Remimazolam is already approved, but the trial focuses on specific high-risk groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD III/IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regional Institute of Gastroenterology-Hepatology Prof. Dr. Octavian Fodor
Cluj-Napoca, Cluj, Romania